A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
Public ClinicalTrials.gov record NCT04772989. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies
Study identification
- NCT ID
- NCT04772989
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Enrollment
- 94 participants
Conditions and interventions
Conditions
Interventions
- AB308 Drug
- Zimberelimab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 18, 2021
- Primary completion
- Aug 24, 2025
- Completion
- Aug 24, 2025
- Last update posted
- Aug 27, 2025
2021 – 2025
United States locations
- U.S. sites
- 15
- U.S. states
- 15
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Department of Medicine - Hematology/Oncology | Los Angeles | California | 90095 | — |
| Mayo Clinic Jacksonville - PPDS | Jacksonville | Florida | 32224 | — |
| Goshen Health System | Goshen | Indiana | 46526 | — |
| Holden Comprehensive Cancer Center | Iowa City | Iowa | 52242 | — |
| Norton Cancer Insititute-Downtown | Louisville | Kentucky | 40202 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| Columbia University Medical Center | New York | New York | 10032-3729 | — |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| University of Oklahoma Peggy and Charles Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15240 | — |
| Tennessee Onocology - Nashville | Nashville | Tennessee | 37205 | — |
| START South Texas Accelerated Research Therapeutics | San Antonio | Texas | 78229 | — |
| START South Texas Accelerated Research Therapeutics - Mountain Region | West Valley City | Utah | 84119 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22033-1712 | — |
| University of Wisconsin - Madison | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04772989, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04772989 live on ClinicalTrials.gov.